Literature DB >> 32489804

World Heart Federation Briefing on Prevention: Coronavirus Disease 2019 (COVID-19) in Low-Income Countries.

Friedrich Thienemann1,2,3, Fausto Pinto3,4, Diederick E Grobbee3,5, Michael Boehm6, Nooshin Bazargani3, Junbo Ge3,7, Karen Sliwa1,3.   

Abstract

In December 2019, the novel coronavirus Coronavirus Disease 2019 (COVID-19) outbreak started in Wuhan, the capital of Hubei province in China. Since then it has spread to many other regions, including low-income countries. Copyright:
© 2020 The Author(s).

Entities:  

Keywords:  Africa; COVID-19; cardiovascular disease; coronavirus; low income countries; middle income countries

Mesh:

Year:  2020        PMID: 32489804      PMCID: PMC7218761          DOI: 10.5334/gh.778

Source DB:  PubMed          Journal:  Glob Heart        ISSN: 2211-8160


In December 2019, the novel coronavirus Coronavirus Disease 2019 (COVID-19) outbreak started in Wuhan, the capital of Hubei province in China. Since then it has spread to many other regions, including low-income countries [12]. The coronavirus was named SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) and has spread to 78 countries (including many low-income countries), with a total of 92,818 confirmed cases globally as of 03 March 2020 (Figure 1). On 30 January 2020, the World Health Organization (WHO) declared the outbreak a ‘public health emergency of international concern’. The first ten cases have now been reported in Africa (Algeria, Egypt, Morocco, Nigeria and Senegal). The spread onto the African continent is of great concern for multiple reasons [3]. Large and densely populated areas and townships with widespread poverty and high migration are the most vulnerable populations for airborne pandemics. Moreover, existing epidemics of human immunodeficiency virus (HIV), tuberculosis (TB) and malaria are likely to collide with COVID-19 and may lead to an increased morbidity and mortality – not reported yet from affected countries. In addition, the wide spread of non-communicable diseases in Africa, such as chronic obstructive pulmonary disease (COPD), heart disease, hypertension and diabetes are known risk factors for severe causes of COVID-19 [2].
Figure 1

Global map of SARS-CoV-2/COVID-19 epidemic by region.

Global map of SARS-CoV-2/COVID-19 epidemic by region. During the past 20 years, outbreak and prevalence of severe respiratory infections have been seen as a major hazard to global health. In December 2019, a series of pneumonia cases of unknown aetiology were documented in Wuhan. High-throughput sequencing from respiratory tract samples revealed this novel coronavirus strain, named SARS-CoV-2 [4]. In response to this outbreak, most areas in China have initiated policies to restrict access and traffic, as well as other measures according to the national prevention and control plan. China’s strong response to containing the COVID-19 epidemic was best practice and exemplary to the world. Back in 2003, there were 305 cases (including five deaths) caused by the outbreak of Severe Acute Respiratory Syndrome (SARS-CoV) before the Chinese government reported it to the WHO on 10 February 2003. However, there were only 27 cases (and no deaths) due to COVID-19 before it was reported to the WHO in January 2020. Since then, the global clinical and scientific community has established guidelines for prevention, diagnosis and management and is working continuously on therapeutic compounds and vaccines. As a global organization representing the cardiovascular community, with more than 200 cardiovascular societies and foundations, the World Heart Federation is concerned that previous studies on other coronavirus diseases such as SARS-CoV and MERS-CoV have demonstrated a relationship between cardiovascular disease (cardiac disease and hypertension), diabetes and an increased morbidity and mortality due to coronavirus disease [56]. Guan et al. reported in the New England Journal of Medicine on a case series of 1,099 cases with COVID-19 admitted to hospital in China. Patients with co-morbidities such as COPD, coronary artery and cerebrovascular disease, hypertension and diabetes were more likely to develop severe COVID-19 disease compared to patients without co-morbidities [2]. Another unpublished case series reported that about 10% of COVID-19 with severe disease developed acute cardiac injury with raised troponin-I/T (Bo Li et al, Clinical Research Cardiology, 2020, in press). The goal of this document is to update our members from low-income countries on important facts on COVID-19 prevention in low- and middle-income countries.

Important facts

1. The novel coronavirus

Coronaviruses belong to a family of viruses that can cause mild disease such as a common cold, but also severe respiratory disease such as Middle East Respiratory Syndrome (MERS-CoV) or Severe Acute Respiratory Syndrome (SARS-CoV). The novel coronavirus epidemic Coronavirus Disease 2019 (COVID-19) is caused by a coronavirus named SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2).

2. Transmission and infection

SARS-CoV-2 is thought to have a zoonotic origin and was first isolated from patients with pneumonia in Wuhan, China. The spread from human-to-human is mainly an aerosol transmission through contaminated respiratory droplets (coughing and sneezing). In addition, respiratory droplets containing the virus may contaminate surfaces up to 96 hours, for example screens of smart phones (Figure 2).
Figure 2

Transmission and infection.

Transmission and infection.

3. Signs and symptoms

Signs and symptoms of COVID-19 include flu-like symptoms such as fever, cough, fatigue, headache, sore throat, shortness of breath and myalgia. In rare cases nausea, vomiting and diarrhoea have occurred. In severe cases pneumonia, acute respiratory distress syndrome (ARDS), multi-organ failure and death have been reported (Figure 3).
Figure 3

Signs and symptoms.

Signs and symptoms.

4. Prevention

Basic recommendations to prevent COVID-19: Follow six easy rules to reduce the risk of coronavirus transmission. The rules are built on the principle of protecting yourself and protecting others (Figure 4).
Figure 4

Prevention.

Prevention.

Recommendations on prevention for special populations

People with chronic underlying disease may be at increased risk of severe COVID-19 disease and death (Table 1). In the largest Chinese cohort, 16% of patients developed severe disease with a mortality rate of 8.1% [2]. Of those patients with severe disease, 38.7% had co-morbidities. Therefore, patients with co-morbidities require more rigorous prevention mechanisms. For people with chronic respiratory disease (e.g. chronic obstructive airways disease), infectious diseases (e.g. HIV and tuberculosis), chronic cardiovascular disease (e.g. cardiomyopathy, previous myocardial infarction, rheumatic heart disease), cancer or autoimmune diseases we recommend:
Table 1

Risk factors for severe disease.

Risk factors for severe disease

1. Age>52 years (interquartile range 40–65)
2. Co-morbiditiespresent in 38% of patients with severe diseaseHypertension 24%Diabetes 16%Coronary heart or cerebrovascular disease 8%Chronic obstructive pulmonary disease (COPD) 4%Chronic kidney disease 2%Cancer 2%
3. Additional risk factor unique for low-income countriesHIVTuberculosisChronic obstructive pulmonary disease (COPD)Rheumatic heart disease (RHD)Cardiomyopathies

The table outlines risk factors for severe COVID-19 disease and co-morbidities from China (from Guan et al. Clinical characteristics of coronavirus disease 2019 in China, NEJM, 2020) and low-income settings with a focus on Sub-Saharan Africa.

Avoid large gatherings – stay at home. Keep at least 1–2 meters distance from a person with respiratory symptoms and do not stay in the same room with this person. Vulnerable people should consider moving to relatives in rural areas and spend their time in voluntary isolation, such as a small hut, receiving food supplies via a neighbour or relative, but without direct contact. Travel should be reduced to a minimum. Use a mask if travelling in a bus, train or plane. If masks are not available or affordable, cover your nose and mouth with a cloth or similar. Risk factors for severe disease. The table outlines risk factors for severe COVID-19 disease and co-morbidities from China (from Guan et al. Clinical characteristics of coronavirus disease 2019 in China, NEJM, 2020) and low-income settings with a focus on Sub-Saharan Africa. In case SARS-CoV-2/COVID-19 begins to spread in low-income countries at high risk of airborne diseases, as described above, containment may not be realistic and response efforts will likely need to transition to various mitigation strategies, which could include isolating ill people at home, closing schools, universities, places of religious worship and public events, which would also include attending funerals. Please follow recommendations of leading health organizations as outlined in Table 2.
Table 2

Important resources and information.


World Health Organizationwww.who.int/health-topics/coronaviru
European Centre for Disease Prevention and Controlwww.ecdc.europa.eu/en/coronavirus
US Centers for Disease Control and Preventionwww.cdc.gov/coronavirus/2019-nCoV
Uptodatewww.uptodate.com/contents/coronavirus-disease-2019-covid-19

Important resources and information.
  5 in total

1.  Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS.

Authors:  J K Yang; Y Feng; M Y Yuan; S Y Yuan; H J Fu; B Y Wu; G Z Sun; G R Yang; X L Zhang; L Wang; X Xu; X P Xu; J C N Chan
Journal:  Diabet Med       Date:  2006-06       Impact factor: 4.359

Review 2.  Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis.

Authors:  Alaa Badawi; Seung Gwan Ryoo
Journal:  Int J Infect Dis       Date:  2016-06-21       Impact factor: 3.623

3.  A Novel Coronavirus from Patients with Pneumonia in China, 2019.

Authors:  Na Zhu; Dingyu Zhang; Wenling Wang; Xingwang Li; Bo Yang; Jingdong Song; Xiang Zhao; Baoying Huang; Weifeng Shi; Roujian Lu; Peihua Niu; Faxian Zhan; Xuejun Ma; Dayan Wang; Wenbo Xu; Guizhen Wu; George F Gao; Wenjie Tan
Journal:  N Engl J Med       Date:  2020-01-24       Impact factor: 91.245

4.  Looming threat of COVID-19 infection in Africa: act collectively, and fast.

Authors:  John N Nkengasong; Wessam Mankoula
Journal:  Lancet       Date:  2020-02-27       Impact factor: 79.321

5.  An interactive web-based dashboard to track COVID-19 in real time.

Authors:  Ensheng Dong; Hongru Du; Lauren Gardner
Journal:  Lancet Infect Dis       Date:  2020-02-19       Impact factor: 25.071

  5 in total
  18 in total

1.  Cardiovascular Risk Factors and Clinical Outcomes among Patients Hospitalized with COVID-19: Findings from the World Heart Federation COVID-19 Study.

Authors:  Dorairaj Prabhakaran; Kavita Singh; Dimple Kondal; Lana Raspail; Bishav Mohan; Toru Kato; Nizal Sarrafzadegan; Shamim Hayder Talukder; Shahin Akter; Mohammad Robed Amin; Fastone Goma; Juan Gomez-Mesa; Ntobeko Ntusi; Francisca Inofomoh; Surender Deora; Evgenii Philippov; Alla Svarovskaya; Alexandra Konradi; Aurelio Puentes; Okechukwu S Ogah; Bojan Stanetic; Aurora Issa; Friedrich Thienemann; Dafsah Juzar; Ezequiel Zaidel; Sana Sheikh; Dike Ojji; Carolyn S P Lam; Junbo Ge; Amitava Banerjee; L Kristin Newby; Antonio Luiz P Ribeiro; Samuel Gidding; Fausto Pinto; Pablo Perel; Karen Sliwa
Journal:  Glob Heart       Date:  2022-06-15

2.  Mitigating the Risk of COVID-19 Deaths in Cardiovascular Disease Patients in Africa Resource Poor Communities.

Authors:  Ihunanya Chinyere Okpara; Efosa Kenneth Oghagbon
Journal:  Front Cardiovasc Med       Date:  2021-02-16

3.  Dual Challenge of Cancer and COVID-19: Impact on Health Care and Socioeconomic Systems in Asia Pacific.

Authors:  Roselle De Guzman; Monica Malik
Journal:  JCO Glob Oncol       Date:  2020-06

4.  Does communicable diseases (including COVID-19) may increase global poverty risk? A cloud on the horizon.

Authors:  Muhammad Khalid Anser; Zahid Yousaf; Muhammad Azhar Khan; Abdelmohsen A Nassani; Saad M Alotaibi; Muhammad Moinuddin Qazi Abro; Xuan Vinh Vo; Khalid Zaman
Journal:  Environ Res       Date:  2020-05-15       Impact factor: 6.498

5.  Relational solidarity and COVID-19: an ethical approach to disrupt the global health disparity pathway.

Authors:  Anita Ho; Iulia Dascalu
Journal:  Glob Bioeth       Date:  2021-03-15

6.  Health, psychosocial, and economic impacts of the COVID-19 pandemic on people with chronic conditions in India: a mixed methods study.

Authors:  Kavita Singh; Dimple Kondal; Sailesh Mohan; Suganthi Jaganathan; Mohan Deepa; Nikhil Srinivasapura Venkateshmurthy; Prashant Jarhyan; Ranjit Mohan Anjana; K M Venkat Narayan; Viswanathan Mohan; Nikhil Tandon; Mohammed K Ali; Dorairaj Prabhakaran; Karen Eggleston
Journal:  BMC Public Health       Date:  2021-04-08       Impact factor: 3.295

Review 7.  Coronavirus Disease 2019 (COVID-19) and its implications for cardiovascular care: expert document from the German Cardiac Society and the World Heart Federation.

Authors:  Michael Böhm; Norbert Frey; Evangelos Giannitsis; Karen Sliwa; Andreas M Zeiher
Journal:  Clin Res Cardiol       Date:  2020-05-27       Impact factor: 5.460

Review 8.  COVID-19: A perspective on Africa's capacity and response.

Authors:  Tafadzwa Dzinamarira; Mathias Dzobo; Itai Chitungo
Journal:  J Med Virol       Date:  2020-06-24       Impact factor: 20.693

Review 9.  The potential similarities of COVID-19 and autoimmune disease pathogenesis and therapeutic options: new insights approach.

Authors:  Sahar Najafi; Elham Rajaei; Rezvan Moallemian; Forough Nokhostin
Journal:  Clin Rheumatol       Date:  2020-09-03       Impact factor: 3.650

10.  The World Heart Federation Global Study on COVID-19 and Cardiovascular Disease.

Authors:  Karen Sliwa; Kavita Singh; Lana Raspail; Dike Ojji; Carolyn S P Lam; Friedrich Thienemann; Junbo Ge; Amitava Banerjee; L Kristin Newby; Antonio Luiz P Ribeiro; Samuel Gidding; Fausto Pinto; Pablo Perel; Dorairaj Prabhakaran
Journal:  Glob Heart       Date:  2021-04-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.